Treatment of primary hepatic carcinoma by transcatheter arterial perfusion of batroxobin combined with TACE:a preliminary clinical study

作     者：Tianjun Gao Mingwu Lou Hui Wang Yi Fan Yunxia Shen Jiyin Ruan Hongguang Zhang 

作者机构：Department of Interventional Radiology Longgang District Central Hospital of Shenzhen Shenzhen 518116 China Department of Intervention Tumour Hospital of Jilin Province Changchun 130012 China 

出 版 物：《The Chinese-German Journal of Clinical Oncology》 (中德临床肿瘤学杂志（英文版）)

年 卷 期：2011年第10卷第2期

页      面：96-99页

学科分类：090603[农学-临床兽医学] 1002[医学-临床医学] 0907[农学-林学] 090705[农学-野生动植物保护与利用] 09[农学] 0906[农学-兽医学] 

基　　金：Supported by a grant from the Sciences and Technology Foundation of Guangdong Province (No. 73128) 

主　　题：batroxobin liver neoplasms fibrinogen therapy transcatheter arterial chemoembolization(TACE) 

摘      要：Objective:The aim of the study was to explore the therapeutic efficacy and safety of batroxobin in patients with primary hepatic carcinoma(PHC) and the advantages of transcatheter arterial perfusion of batroxobin combined with transcatheter arterial chemoembolization(TACE).Methods:Forty patients with PHC were randomized into experimental group(transcatheter arterial perfusion of batroxobin combined with TACE treatment,20 patients) and control group(TACE alone group,20 patients).The patients were followed up and the data were recorded,compared and ***:(1) Compared with the control group,the FIB level in the experimental group was significantly decreased at the first month after treatment(P 0.05).Conclusion:Batroxobin can rapidly and effectively decrease the FIB level of the PHC *** it may be used as an effective and safe adjuvant drug for the treatment of primary hepatic *** arterial perfusion of batroxobin combined with TACE therapy has advantages in comparison with TACE alone *** could be taken as a new therapeutic regimen in the PHC treatment.